medicina57巻3号

2020年03月発行

特集 症状・治療歴から考える—薬の副作用の診断プロセス問題集60題 総論

薬物有害事象，薬物有害反応に対処する—リスクのない薬はない！　慎重投与のすすめ

著者： 宮田靖志¹

所属機関： ¹愛知医科大学地域総合診療医学寄附講座

ページ範囲：P.430 - P.436

Point
◎薬物のエラーによる患者の害は，想像以上に多く発生していることを肝に銘じるべきである．
◎薬物有害反応の診断は難しい．Naranjoのスケールで積極的に診断を試みる必要がある．
◎薬物有害事象のほとんどはシステムエラーから生じている．60％は予防可能である．
◎本当に新薬を使用する必要性があるのか，きちんと見極める必要がある．

参考文献

1）WHO launches global effort to halve medication-related errors in 5 years. March 29, 2017.　http://www.who.int/mediacentre/news/releases/2017/medication-related-errors/en/（2020年1月閲覧）

2）Kohn LT, et al：To Err Is Human：Building a Safer Health System. National Academy Press, Washington, 2000

3）Schatz SN, Weber RJ：Adverse Drug Reactions. CNS/Pharmacy Practice. PSAP. American College of Clinical Pharmacy；2015.　https://www.accp.com/docs/bookstore/psap/2015B2.SampleChapter.pdf（2020年1月閲覧）

4）Schatz SN, Weber RJ：Adverse Drug Reactions. CNS/Pharmacy Practice. PSAP. American College of Clinical Pharmacy；2015.　https://www.accp.com/docs/bookstore/psap/2015B2.SampleChapter.pdf（2020年1月閲覧）

5）Ionnidis PA, et al：Better reporting of harms in randomized trials：An extension of the CONSORT statement. Ann Intern Med 141：781-788, 2004

6）WHO technical report No.498. WHO（1972）WHO technical report no. 498. International drug monitoring：the role of national centres.　https://www.who-umc.org/media/2680/who-technical-report-498.pdf（2020年1月閲覧）

7）Bates DW, et al：Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 274：29-34, 1995

8）Abhinav Kant, et al：Adverse Drug Reactions. Hugh C. Hemmings, Jr., Talmage D. Egan（ed）：Pharmacology and Physiology for Anesthesia, 2nd ed. pp130-143, Elsevier, Philadelphia, 2019

9）Gandhi TK, et al：Identifying drug safety issues：from research to practice. Int J Qual Health Care 12：69-76, 2000

10）Donaldson LJ, et al：Medication without harm：WHO's Third Global Patient Safety Challenge. Lancet 389：1680-1681, 2017

11）Classification of adverse drug reactions. In：Pichler WJ, ed. Drug hypersensitivity：Classification and Clinical Features. UpToDate.　https://www.uptodate.com/contents/drug-allergy-classification-and-clinical-features（2020年1月閲覧）

12）Fotis M, Budris W：Clinical Analysis of Adverse Drug Reactions. Atkinson A, Jr., et al（ed）：Principles of Clinical Pharmacology, 3rd ed. pp455-465, Academic Press, New York, 2012

13）Naranjo CA, et al：A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30：239-245, 1981

14）Ferner RE, McGettigan P：Adverse drug reactions. BMJ 363：k4051, 2018

15）Link E, et al：SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 359：789-799, 2008

16）Roden DM：Chapter 21：Adverse Drug Events. Robertson D, Williams G（ed）：Clinical and Translational Science, 2nd ed, pp389-396, Academic Press, New York, 2017

17）Hauben M, Aronson JK：Gold standards in pharmacovigilance：The use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore. Drug Saf 30：645-655, 2007

18）Hanley MJ, et al：Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49：71-87, 2010

19）Raut AL, et al：Preventability, predictability and seriousness of adverse drug reactions amongst medicine inpatients in a teaching hospital：A prospective observational study. Int J Pharm Chem Sci 1：1293e1299, 2012

20）Junya Zhu, et al：Prevention of drug event in hospitals. UpToDate Version 21.0

21）Medication Errors in Nursing：Common Types, Causes, and Prevention. Medcomm.　https://www.medcomrn.com/index.php/articles/commonnursing-medication-errors-types-causes-prevention/（2020年1月閲覧）

22）Schiff GD, et al：Principles of conservative prescribing. Arch Intern Med 171：1433-1440, 2011